ABT vs GILD
ABT: Abbott is a diversified healthcare conglomerate manufacturing diagnostics, nutritional products, pharmaceuticals, and medical devices with recent expansion into cancer diagnostics through Exact Sciences acquisition. GILD: A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis, and cancer.
Side-by-side fundamentals
| Metric | ABT | GILD | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $94.40 | $134.84 | |
| Market cap as of 2026-07-10 | $164.5B | $166.0B | |
| P/E as of 2026-07-10 | 26.21 | 18.01 | GILD lower |
| PEG as of 2026-07-10 | 2.66 | 1.94 | GILD lower |
| Net margin as of 2026-07-10 | +13.9% | +31.0% | GILD higher |
| Gross margin as of 2026-07-10 | +56.5% | +79.3% | GILD higher |
| Operating margin as of 2026-07-10 | +17.1% | +34.9% | GILD higher |
| ROE as of 2026-07-10 | +12.2% | +42.2% | GILD higher |
| ROA as of 2026-07-10 | +6.9% | +16.1% | GILD higher |
| Debt / equity as of 2026-07-10 | 0.65 | 0.94 | ABT lower |
| Revenue growth (YoY) as of 2026-07-10 | +6.6% | +3.5% | ABT higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +2.6% | GILD higher |
| Dividend yield as of 2026-07-10 | +2.6% | +2.4% | ABT higher |
| Dividend streak (yrs) SEC XBRL | 4 | 5 | GILD higher |
| Beta as of 2026-07-10 | 0.59 | 0.34 | |
| 1-year return as of 2026-07-09 close | -29.1% | +19.1% | GILD higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.